Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.

abstract：PURPOSE:Clinical data suggested that a regimen incorporating doxorubicin to 5-fluorouracil (5-FU) and cisplatin may be more effective but probably quite toxic for advanced gastric cancer patients. With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, ci...

journal_title：Cancer chemotherapy and pharmacology

authors： Cascinu S,Galizia E,Labianca R,Ferraù F,Pucci F,Silva RR,Luppi G,Beretta GD,Berardi R,Scartozzi M

更新日期：2011-07-01 00:00:00

abstract：:Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and ce...

journal_title：Cancer chemotherapy and pharmacology

authors： Bogush T,Smirnova G,Shubina I,Syrkin A,Robert J

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:The level of drug metabolism and drug transport is correlated with the sensitivity of cancer cells towards platinum-based chemotherapy. We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which...

journal_title：Cancer chemotherapy and pharmacology

authors： Sun N,Sun X,Chen B,Cheng H,Feng J,Cheng L,Lu Z

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:Cisplatin and radiation therapy remain the current standard for treating locally advanced SCCHN. Novel treatment approaches are needed, especially in patients with human papilloma virus (HPV)-negative disease who have worse outcomes despite multimodality therapy. METHODS:Using our institutional review board ap...

journal_title：Cancer chemotherapy and pharmacology

authors： Patel K,Wen J,Magliocca K,Muller S,Liu Y,Chen ZG,Saba N,Diaz R

更新日期：2014-11-01 00:00:00

abstract：:The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor rec...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukushima T,Wakatsuki Y,Kobayashi T,Sonehara K,Tateishi K,Yamamoto M,Masubuchi T,Yoshiike F,Hirai K,Hachiya T,Koizumi T

更新日期：2018-06-01 00:00:00

abstract：PURPOSE:We conducted a phase II study of combination chemotherapy with nedaplatin (NP) and irinotecan (CPT) followed by gefitinib to determine the effects and toxicities in patients 70 years or older with unresectable non-small cell lung cancer (NSCLC). METHODS:Eligible patients were entered to receive 3 courses of 50...

journal_title：Cancer chemotherapy and pharmacology

authors： Oshita F,Yamada K,Saito H,Noda K

更新日期：2008-08-01 00:00:00

abstract：:We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsukuda M,Ishitoya J,Matsuda H,Horiuchi C,Taguchi T,Takahashi M,Nishimura G,Kawakami M,Watanabe M,Niho T,Kawano T,Ikeda Y,Sakuma Y,Shiono O,Komatsu M

更新日期：2010-09-01 00:00:00

abstract：PURPOSE:SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the combination of SU5416 and paclitaxel in recurrent or metastatic c...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Tserng KY,Makar V,McPeak RJ,Ingalls ST,Dowlati A,Overmoyer B,McCrae K,Ksenich P,Lavertu P,Ivy P,Hoppel CL,Remick S

更新日期：2005-03-01 00:00:00

abstract：PURPOSE:This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling. METHODS:Patients with advanced cancers received salirasib twice daily for 21 days every 4 weeks. Doses were escalated from 100 to 200, 400, 600, and 800 mg. RESULTS:The ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsimberidou AM,Rudek MA,Hong D,Ng CS,Blair J,Goldsweig H,Kurzrock R

更新日期：2010-01-01 00:00:00

abstract：:Glycoprotein (gp) 130, a receptor component for interleukin 6 (IL-6), can associate with a soluble IL-6 receptor (sIL-6R)-IL-6 complex. To examine the role of gp130 signaling in human hematopoietic progenitor-cell proliferation and differentiation, we studied the effects of the sIL-6R-IL-6 complex in combination with ...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakahata T,Sui X,Tanaka R,Tajima S,Muraoka K,Ebihara Y,Tsuji K

更新日期：1996-01-01 00:00:00

abstract：OBJECTIVES:To assess the cardiovascular safety, tolerability and efficacy of high doses of granisetron for the treatment of nausea and vomiting in patients undergoing highly emetogenic chemotherapy. METHODS:Patients with histologically confirmed malignant disease were given an intravenous infusion of granisetron, 160 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Carmichael J,Harris AL

更新日期：2004-02-01 00:00:00

abstract：PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

journal_title：Cancer chemotherapy and pharmacology

authors： Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bose P,Perkins EB,Honeycut C,Wellons MD,Stefan T,Jacobberger JW,Kontopodis E,Beumer JH,Egorin MJ,Imamura CK,Douglas Figg W Sr,Karp JE,Koc ON,Cooper BW,Luger SM,Colevas AD,Roberts JD,Grant S

更新日期：2012-06-01 00:00:00

abstract：:The development of nitrosoureas has switched from more lipophilic derivatives to congeners with higher water-solubility, since this property was presumably associated with a decrease in myelosuppression. We have compared the therapeutic efficacy of clinically well-known lipophilic nitrosoureas BCNU, CCNU, and MeCCNU w...

journal_title：Cancer chemotherapy and pharmacology

authors： Osieka R,Glatte P,Pannenbäcker R,Schmidt CG

更新日期：1983-01-01 00:00:00

abstract：:Seven small- (SCLC) and four non-small-cell (NSCLC) lung cancer cell lines were used to examine the in vitro cytotoxicity of cytotoxic drugs such as (1aS-(1a alpha,8 beta,8a alpha,8b alpha]-8-[aminocarbonyl)oxy)methyl)-4,8a- dimethoxy-1,1a,2,8,8a,8b-hexahydro-7-hydroxy-5-methyl-6- nitrosoazirino(2',3':3,4)-pyrrolo-(1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Horiuchi N,Nakagawa K,Sasaki Y,Minato K,Fujiwara Y,Nezu K,Ohe Y,Saijo N

更新日期：1988-01-01 00:00:00

abstract：:Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

journal_title：Cancer chemotherapy and pharmacology

authors： Daoud SS,Juliano RL

更新日期：1989-01-01 00:00:00

abstract：:A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the med...

journal_title：Cancer chemotherapy and pharmacology

authors： Junor E,Davies J,Habeshaw T,Kaye S,Paul J,Rankin E,Reed N,Symonds RP

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:To study the dual mechanism of action of FD137, a 3,3-disubstituted nitrosourea designed to block signaling mediated by the epidermal growth factor receptor (EGFR) on its own and to be hydrolyzed to an inhibitor of EGFR plus a DNA-damaging species. MATERIALS AND METHODS:HPLC was used to determine the half-life...

journal_title：Cancer chemotherapy and pharmacology

authors： Qiu Q,Dudouit F,Matheson SL,Brahimi F,Banerjee R,McNamee JP,Jean-Claude BJ

更新日期：2003-01-01 00:00:00

abstract：:In January 1983, the German Society of Pediatric Oncology started a cooperative trial (MAKEI 83) for non-testicular germ-cell tumors. The pilot phase closed in December 1985. The treatment regimen was stratified according to histology, tumor site and tumor stage. In malignant non-seminomatous germ-cell tumors (mNSGCTs...

journal_title：Cancer chemotherapy and pharmacology

authors： Gobel U,Calaminus G,Häas RJ,Jurgens H,Niethammer D,Ritter J,Spaar HJ,Harms D

更新日期：1989-01-01 00:00:00

abstract：:Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kralovanszky J,Prajda N,Kerpel-Fronius S,Bagrij T,Kiss E,Peters GJ

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (tre...

journal_title：Cancer chemotherapy and pharmacology

authors： Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

更新日期：2016-12-01 00:00:00

abstract：PURPOSE:A refined pharmacodynamic model for toxicity is necessary for successful adaptive control of the administration of an anticancer drug to avoid toxicity. We sought to establish a pharmacodynamic model of leukopenia in a 14-day administration of etoposide. METHODS:Pharmacokinetic data of 32 patients treated with...

journal_title：Cancer chemotherapy and pharmacology

authors： Minami H,Ratain MJ,Ando Y,Shimokata K

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:The blood-brain barrier discriminates the access of several molecules to the brain. This hampers the use of some drugs, as doxorubicin, potentially active for treatment of brain tumors. We explored the feasibility of active modification of the blood-brain barrier protection, by using morphine pretreatment, to a...

journal_title：Cancer chemotherapy and pharmacology

authors： Sardi I,la Marca G,Giovannini MG,Malvagia S,Guerrini R,Genitori L,Massimino M,Aricò M

更新日期：2011-06-01 00:00:00

abstract：:A series of halogen analogs of phosphoramide mustard, isophosphoramide mustard, and triphosphoramide mustard, the cytotoxic metabolites of the antitumor drugs cyclophosphamide, ifosfamide, and trofosfamide, respectively, was evaluated in vitro against human tumor cell lines and in vivo against experimental tumors to i...

journal_title：Cancer chemotherapy and pharmacology

authors： Struck RF,Schmid SM,Waud WR

更新日期：1994-01-01 00:00:00

abstract：:Between April 1986 and May 1989 a multicentre study was conducted to evaluate the efficacy of a 4-h intravenous infusion of 1000 mg/m2 5-fluorouracil (5-FU) followed by a 1-h infusion of 25 mg/m2 cisplatin (CDDP) given for 4 consecutive days every 4 weeks to patients with advanced squamous-cell carcinoma of the head a...

journal_title：Cancer chemotherapy and pharmacology

authors： Jassem J,Gyergyay F,Kerpel-Fronius S,Nagykálnai T,Baumöhl J,Verweij J,Vuletic L,Mechl Z,Drozd-Lula M,Jelic S

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as...

journal_title：Cancer chemotherapy and pharmacology

authors： Amato R,Stepankiw M,Gonzales P

更新日期：2013-06-01 00:00:00

abstract：:Some of 66 patients with head and neck tumors were treated with high-dose methotrexate monochemotherapy. The use of a prospective mathematical model with pharmacokinetic surveillance proved to be reliable, practical, and useful. By this means chemotherapy could be individualized, with a resultant marked reduction in t...

journal_title：Cancer chemotherapy and pharmacology

authors： Favre R,Monjanel S,Alfonsi M,Pradoura JP,Bagarry-Liegey D,Clement S,Imbert AM,Lena N,Colonna d'Istria J,Cano JP,Carcassonne Y

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:We reported the first case of phenytoin intoxication due to the concomitant use of phenytoin and TS-1, together with a review of the literature regarding the occurrence of phenytoin intoxication due to the concomitant use of phenytoin and fluoropyrimidine antitumor drugs such as fluorouracil (5-FU) and tegafur ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsuda A,Fujiyama J,Miki A,Hori S,Ohtani H,Sawada Y

更新日期：2008-08-01 00:00:00

abstract：:While N-phosphonacetyl-L-aspartic acid (PALA), an inhibitor of de novo pyrimidine biosynthesis, demonstrated a unique spectrum of activity during preclinical drug evaluation, multiple clinical trials have shown it to possess minimal clinical activity. One explanation for the disappointing results is the possibility th...

journal_title：Cancer chemotherapy and pharmacology

authors： Markman M,Chan TC,Cleary S,Howell SB

更新日期：1987-01-01 00:00:00